metaboliq
PCOS is not confirmed by one test. It is a pattern established across a cycle history, a hormone panel and sometimes a scan — and, critically, only after several other conditions that look identical have been ruled out.
PCOS is diagnosed against a two-of-three framework: irregular ovulation, androgen excess, and polycystic ovarian morphology on ultrasound. So the tests serve that framework. A cycle history, androgen measurements, and the blood tests that exclude other causes come first. An ultrasound is not the entry point many people assume, and it is not required at all when the other two features are already present.
What framework are the tests serving?
The criteria in general use require two of three features: irregular or absent ovulation, clinical or biochemical evidence of raised androgens, and polycystic ovarian morphology on ultrasound. Two of the three, and only once other causes of those same features have been excluded. Understanding that structure explains why the test list looks longer than the condition seems to warrant — a good part of it is there to rule things out rather than to rule PCOS in.
It also explains why no single blood test can confirm it. There is no PCOS marker. Every test on the list is measuring one of the three features, or excluding an impostor.
Why does the cycle history count as data?
Irregular ovulation is one of the three features, and it is usually established from the history rather than from a blood test. How long cycles are, how variable they are, and how long that has been the case. Written down over a few months, this is often the strongest single piece of evidence available, and it costs nothing.
The current guideline is also explicit that the definition of irregular differs by how many years have passed since periods began, because cycles are normally irregular for a period after that point. Applying an adult definition to an adolescent produces over-diagnosis, and the guideline addresses that directly.
Sources: [2]
Which androgens are measured, and when?
Biochemical androgen excess is assessed with total testosterone, usually with sex hormone binding globulin so that a free or calculated free value can be derived, since the bound fraction is not the active one. The awkwardness is that assays for testosterone at the concentrations found in women are known to perform inconsistently, and the guideline says so, recommending high-quality assays and cautioning against over-interpreting borderline values.
Clinical evidence of androgen excess — such as excess hair growth in a male pattern — counts towards the criterion in its own right. That matters, because a person can meet the feature clinically while their blood values sit inside the reference interval.
Timing matters. Androgens are conventionally measured in the early part of a cycle where there is one, and hormonal contraception alters them. A panel taken on the wrong day, or during treatment, can mislead.
What must be excluded, and why it is not optional
Thyroid dysfunction, raised prolactin and non-classic congenital adrenal hyperplasia are the conditions conventionally excluded, because each can produce irregular cycles or androgen features that mimic the picture. That is why thyroid function, prolactin and 17-hydroxyprogesterone appear on a PCOS request form that otherwise looks unrelated to them.
This exclusion step is the part most often skipped when a diagnosis is made quickly, and it is the part with the highest cost of being wrong, since the impostors have different management. A diagnosis reached without it is provisional whether or not anyone said so.
Is an ultrasound always needed?
This is where practice has moved and Indian experience often has not. Under the current guideline, ultrasound is not required for diagnosis where irregular ovulation and androgen excess are both present, since two features are already met and the scan cannot add a third. It also should not be used for diagnosis within eight years of periods beginning, because multifollicular ovaries are common at that stage.
The practical consequence is that a scan is not the entry point many people assume it is. A scan report describing polycystic-appearing ovaries in isolation — with regular cycles and no androgen features — does not establish the condition. Ovarian appearance is one feature of three, not the definition.
Sources: [2]
The metabolic tests that belong beside them
The guideline recommends assessing metabolic features rather than treating the condition as purely reproductive, which in practice means glucose handling, lipids and blood pressure. Reduced insulin sensitivity is documented in PCOS independently of body weight, and the review literature on that mechanism is substantial. That is why these markers belong on the form regardless of what the person weighs.
That is also the part most likely to be left out of a gynaecology-only workup and the part this service is built around. The reproductive diagnosis sits with a treating gynaecologist. The metabolic description of the same person is what a full panel and a physician's reading provide, and the two are complementary rather than competing.